128 related articles for article (PubMed ID: 9781430)
1. Differential expression of hepatocyte growth factor in papillary and nodular tumors of the bladder.
Li B; Kanamaru H; Noriki S; Fukuda M; Okada K
Int J Urol; 1998 Sep; 5(5):436-40. PubMed ID: 9781430
[TBL] [Abstract][Full Text] [Related]
2. Reciprocal expression of bcl-2 and p53 oncoproteins in urothelial dysplasia and carcinoma of the urinary bladder.
Li B; Kanamaru H; Noriki S; Yamaguchi T; Fukuda M; Okada K
Urol Res; 1998; 26(4):235-41. PubMed ID: 9759996
[TBL] [Abstract][Full Text] [Related]
3. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].
Xiao L; Wang CF; Zhu XZ; Yin YL; Chen Y; Lu C; Yu B
Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):319-23. PubMed ID: 21756826
[TBL] [Abstract][Full Text] [Related]
4. Increased DNA methyltransferase 1 protein expression in human transitional cell carcinoma of the bladder.
Nakagawa T; Kanai Y; Saito Y; Kitamura T; Kakizoe T; Hirohashi S
J Urol; 2003 Dec; 170(6 Pt 1):2463-6. PubMed ID: 14634451
[TBL] [Abstract][Full Text] [Related]
5. Expression of transforming growth factor beta1 and its receptors in normal human urothelium and human transitional cell carcinomas.
Izadifar V; de Boer WI; Muscatelli-Groux B; Maillé P; van der Kwast TH; Chopin DK
Hum Pathol; 1999 Apr; 30(4):372-7. PubMed ID: 10208456
[TBL] [Abstract][Full Text] [Related]
6. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.
Nakopoulou L; Vourlakou C; Zervas A; Tzonou A; Gakiopoulou H; Dimopoulos MA
Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder.
Suzuki K; Morita T; Tokue A
Int J Urol; 2005 Feb; 12(2):152-8. PubMed ID: 15733109
[TBL] [Abstract][Full Text] [Related]
8. Functional mononucleotide repeat polymorphism in the promoter region of HGF is associated with risk and malignant aggressiveness of bladder cancer.
Chiba S; Tsuchiya N; Horikawa Y; Narita S; Inoue T; Akihama S; Saito M; Numakura K; Tsuruta H; Huang M; Satoh S; Habuchi T
Int J Oncol; 2014 Mar; 44(3):678-84. PubMed ID: 24366484
[TBL] [Abstract][Full Text] [Related]
9. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder.
Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Navone R
Am J Surg Pathol; 2001 Dec; 25(12):1528-33. PubMed ID: 11717543
[TBL] [Abstract][Full Text] [Related]
10. Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis.
Furukawa T; Duguid WP; Kobari M; Matsuno S; Tsao MS
Am J Pathol; 1995 Oct; 147(4):889-95. PubMed ID: 7573364
[TBL] [Abstract][Full Text] [Related]
11. E-cadherin expression in urothelial carcinoma in situ, superficial papillary transitional cell carcinoma, and invasive transitional cell carcinoma.
Sun W; Herrera GA
Hum Pathol; 2002 Oct; 33(10):996-1000. PubMed ID: 12395372
[TBL] [Abstract][Full Text] [Related]
12. Expression of bcl-2 and p53 oncoproteins in schistosomiasis-associated transitional and squamous cell carcinoma of urinary bladder.
Chaudhary KS; Lu QL; Abel PD; Khandan-Nia N; Shoma AM; el Baz M; Stamp GW; Lalani EN
Br J Urol; 1997 Jan; 79(1):78-84. PubMed ID: 9043502
[TBL] [Abstract][Full Text] [Related]
13. Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder.
May M; Nitzke T; Helke C; Vogler H; Hoschke B
Scand J Urol Nephrol; 2004; 38(3):231-5. PubMed ID: 15204377
[TBL] [Abstract][Full Text] [Related]
14. Expression of hepatocyte growth factor and its receptor C-met in acquired renal cystic disease associated with renal cell carcinoma.
Konda R; Sato H; Hatafuku F; Nozawa T; Ioritani N; Fujioka T
J Urol; 2004 Jun; 171(6 Pt 1):2166-70. PubMed ID: 15126778
[TBL] [Abstract][Full Text] [Related]
15. P53 overexpression in bladder urothelial neoplasms: new aspect of World Health Organization/International Society of Urological Pathology classification.
Kalantari MR; Ahmadnia H
Urol J; 2007; 4(4):230-3. PubMed ID: 18270948
[TBL] [Abstract][Full Text] [Related]
16. Variable Bcl-2 phenotype in benign and malignant lesions of urothelium.
Bilim VN; Tomita Y; Kawasaki T; Takeda M; Takahashi K
Cancer Lett; 1998 Jun; 128(1):87-92. PubMed ID: 9652797
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder.
Shiina H; Igawa M; Urakami S; Honda S; Shirakawa H; Ishibe T
J Clin Pathol; 1996 May; 49(5):395-9. PubMed ID: 8707954
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.
Popov Z; Gil-Diez-De-Medina S; Ravery V; Hoznek A; Bastuji-Garin S; Lefrere-Belda MA; Abbou CC; Chopin DK
Urol Oncol; 2004; 22(2):93-101. PubMed ID: 15082004
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of HGF, c-MET and transcription factor STAT3 in colorectal tumors.
Trovato M; Vitarelli E; Grosso M; Alesci S; Benvenga S; Trimarchi F; Barresi G
Eur J Histochem; 2004; 48(3):291-7. PubMed ID: 15590419
[TBL] [Abstract][Full Text] [Related]
20. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.
Karam JA; Shariat SF; Huang HY; Pong RC; Ashfaq R; Shapiro E; Lotan Y; Sagalowsky AI; Wu XR; Hsieh JT
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4400-6. PubMed ID: 17671122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
